Alto Neuroscience reports full-year 2025 results — EEG-guided precision psychiatry drug trials advancing
Summary
Alto Neuroscience reported full-year 2025 financial results and business highlights, demonstrating progress in their EEG biomarker-guided precision psychiatry platform. The company uses quantitative EEG to stratify psychiatric patients into biologically defined subgroups and match them to specific drug candidates — enabling clinical trials that enroll only patients predicted to respond, dramatically improving success rates versus traditional diagnostic-category-based enrollment. Alto's model positions them as both a drug developer and an EEG biomarker platform company.
Why it matters
Alto Neuroscience's EEG-guided patient stratification directly addresses the primary reason psychiatric drug trials fail: treating biologically heterogeneous patient populations as if they were homogeneous. By using qEEG to enroll only predicted responders, Alto could achieve the phase 2 success rates (70%+) that oncology achieves with biomarker-selected trials versus psychiatry's historical 40-50% success rate.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial